Have a personal or library account? Click to login
Efficacy and Toxicity of Maintenance Pemetrexed Following Induction Treatment with Pemetrexed Plus Cisplatin for Advanced Non-small-cell Non-squamous Carcinoma of the Lung Cover

Efficacy and Toxicity of Maintenance Pemetrexed Following Induction Treatment with Pemetrexed Plus Cisplatin for Advanced Non-small-cell Non-squamous Carcinoma of the Lung

Forum of Clinical Oncology
Volume 6 (2015): Issue 2 (June 2015)
By: D. H. Kim,  A. Kinmond,  S. Gilani,  S. Giridharan and  A. Jegannathen  
Open Access
|Jun 2015

References

  1. [1] Jemal A, Bray F, Center MM et al. Global cancer statistics. CA Cancer J Clin. 2011; 61: 69-90.10.3322/caac.20107
    Search in Google Scholar
  2. [2] Früh M, De Ruysscher D, Popat S, et al. Small-cell lung cancer (SCLC): ESMO Clinical
    Search in Google Scholar
  3. [3] Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2013; 24 (6): vi99- vi105.10.1093/annonc/mdt178
    Search in Google Scholar
  4. [4] Li X, Wei S, Chen J. Critical appraisal of pemetrexed in the treatment of NSCLC and metastatic pulmonary nodules. Onco Targets Ther. 2014;7:937-45.
    Search in Google Scholar
  5. [5] Swisher SG. Surgical treatment of locally advanced non-small cell lung cancer. In: Fossella FV, Komaki R, Putnam JB Jr, eds. Lung Cancer. New York, NY: Springer, 2002: 118-41.
    Search in Google Scholar
  6. [6] Peters S, Adjei AA, Gridelli C, et al. Metastatic nonsmall- cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 2012; 23 (7): vii56- vii64.10.1093/annonc/mds226
    Search in Google Scholar
  7. [7] National Institute for Health and Clinical Excellence. Pemetrexed for the maintenance treatment of non-small-cell lung cancer. TA190. June 2010. Available at: http://www.nice.org.uk/guidance/TA190.
    Search in Google Scholar
  8. [8] Paz-Ares LG, de Marinis F, Dediu M, et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-smallcell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol. 2012; 13(3):247-55.10.1016/S1470-2045(12)70063-3
    Search in Google Scholar
  9. [9] Paz-Ares LG, de Marinis F, Dediu M, et al. PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol. 2013; 31(23):2895-902.10.1200/JCO.2012.47.110223835707
    Search in Google Scholar
  10. [10] Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-16.10.1093/jnci/92.3.20510655437
    Search in Google Scholar
  11. [11] Common Terminology Criteria for Adverse Events v3.0 (CTCAE), 8/2006 update. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf (accessed March, 2014).
    Search in Google Scholar
  12. [12] Oken, MM, Creech, RH, Tormey DC, et al. Toxicity And Response Criteria Of The Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982; 5:649-655.10.1097/00000421-198212000-00014
    Search in Google Scholar
  13. [13] Minami S, Kijima T, Komuta K, et al. Phase II trial of pemetrexed continuation--maintenance after carboplatin-based induction in untreated nonsquamous non-small cell lung cancer. Anticancer Res. 2013; 33(12):5535-42.
    Search in Google Scholar
  14. [14] Brodowicz T, Krzakowski M, Zwitter M, et al. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: A phase III trial. Lung Cancer. 2006; 52:155-163.10.1016/j.lungcan.2006.01.00616569462
    Search in Google Scholar
  15. [15] Belani CP, Waterhouse DM, Ghazal H, et al. Phase III study of maintenance gemcitabine (G) and best supportive care (BSC) versus BSC, following standard combination therapy with gemcitabine carboplatin (G-Cb) for patients with advanced nonsmall cell lung cancer (NSCLC). J Clin Oncol. 2010; 28:540s.10.1200/jco.2010.28.15_suppl.7506
    Search in Google Scholar
DOI: https://doi.org/10.1515/fco-2015-0008 | Journal eISSN: 1792-362X | Journal ISSN: 1792-345X
Journal RSS Feed
Language: English
Page range: 14 - 18
Published on: Jun 30, 2015
Published by: Helenic Society of Medical Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 2 issues per year
Keywords:
Pemetrexed,
Maintenance Pemetrexed,
Cisplatin,
Advanced lung cancer,
non-small cell,
non-squamous,
Efficacy and Toxicity
Related subjects:
Medicine,
Clinical medicine,
Internal medicine,
Haematology, oncology

© 2015 D. H. Kim, A. Kinmond, S. Gilani, S. Giridharan, A. Jegannathen, published by Helenic Society of Medical Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Previous articleVolume 6 (2015): Issue 2 (June 2015)Next article